Theranostics targeting fibroblast activation protein using [64Cu]FAPI-04: biodistribution in human pancreatic cancer xenograft mice with histological confirmation

Conclusions: This study showed the feasibility of [64Cu]FAPI-04 for the diagnosis of FAP-expressing pancreatic cancer. Since the half-life of 64Cu (12.7 hrs) is longer than 68Ga (68mins), it’s possible to trace the biodistribution of FAPI-04 for a longer time, which enables precise pre-treatment evaluation for the targeted radionuclide therapy using Lu-177 (6.7 days) or 225Ac (10 days).Fig.1 Delayed PET imaging of PANC-1 and MIAPaCa2 xenograft models.Fig.2 The uptake in the tumor and normal organs at the delayed PET scan.Fig.3 Immunohistochemical staining of the PANC-1 tumor xenograft using FAP-alpha antibody (left: low magnification, right: high magnification).

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Liu, Y., Watabe, T., Shirakami, Y., Lindner, T., Kaneda-Nakashima, K., Ooe, K., Naka, S., Shimosegawa, E., Haberkorn, U., Giesel, F., Hatazawa, J. Tags: Preclinical Probes for Oncology Posters Source Type: research